KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 85 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,000 | +2.5% | 4,226 | -5.9% | 0.00% | – |
| Q2 2023 | $40,000 | +263.6% | 4,492 | +225.7% | 0.00% | – |
| Q1 2023 | $11,000 | -62.1% | 1,379 | -68.2% | 0.00% | – |
| Q4 2022 | $29,000 | -79.7% | 4,332 | -56.0% | 0.00% | – |
| Q3 2022 | $143,000 | +14200.0% | 9,847 | +7035.5% | 0.00% | – |
| Q2 2022 | $1,000 | -95.0% | 138 | -90.0% | 0.00% | – |
| Q1 2022 | $20,000 | -69.7% | 1,376 | -72.3% | 0.00% | – |
| Q4 2021 | $66,000 | +61.0% | 4,971 | +113.8% | 0.00% | – |
| Q3 2021 | $41,000 | -41.4% | 2,325 | -19.8% | 0.00% | – |
| Q2 2021 | $70,000 | +52.2% | 2,900 | +62.2% | 0.00% | – |
| Q1 2021 | $46,000 | +253.8% | 1,788 | +166.9% | 0.00% | – |
| Q4 2020 | $13,000 | – | 670 | +3090.5% | 0.00% | – |
| Q3 2020 | $0 | – | 21 | -34.4% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 32 | -97.5% | 0.00% | – |
| Q4 2019 | $22,000 | – | 1,263 | +12530.0% | 0.00% | – |
| Q3 2018 | $0 | – | 10 | +900.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |